Within the investing sport, it’s not solely about what you purchase; it’s about whenever you purchase it. One of the crucial frequent items of recommendation thrown across the Road, “purchase low” is touted as a tried-and-true tactic.Positive, the technique appears easy. Inventory costs naturally fluctuate on the premise of a number of components like earnings outcomes and the macro surroundings, amongst others, with traders making an attempt to time the market and decide when shares have hit a backside. In follow, nevertheless, executing on this technique is not any straightforward activity.On high of this, given the volatility that has dominated the markets over the previous few weeks, how are traders purported to gauge when a reputation is flirting with a backside? That’s the place the Wall Road execs are available in.These knowledgeable inventory pickers have recognized three compelling tickers whose present share costs land near their 52-week lows. Noting that every is about to take again off on an upward trajectory, the analysts see a horny entry level. Utilizing TipRanks’ database, we discovered that the analyst consensus has rated all three a Robust Purchase, with main upside potential additionally on faucet.Progenity (PROG)Providing clear and actionable genetic outcomes, Progenity makes a speciality of offering testing providers. The corporate began buying and selling on Nasdaq in June and noticed its shares tumbling 44% since then. With shares altering palms for $8.11, a number of members of the Road suggest pulling the set off earlier than it heats up.Piper Sandler analyst Steven Mah factors out that even in opposition to the backdrop of COVID-19, PROG managed to ship with its Q2 2020 efficiency. “We’re inspired by the restoration in late Q2 2020 with 75,000 accessioned checks (~79,000 in Q1 2020), pushed by noninvasive prenatal testing (NIPT) and provider screening,” the analyst famous. Expounding on this, Mah said, “Progenity didn’t present steerage, however June check volumes of ~28,000 have been robust (Q1 2020 month-to-month common was ~26,000) which we imagine showcases the sturdiness of its reproductive checks and the success that Progenity has in co-marketing and attaching provider screening to the extra important NIPT. Of word, regardless of the pandemic disruptions, Progenity was in a position to keep its main pre-COVID check turnaround occasions.”Moreover, well being insurer Aetna is quickly extending protection of average-risk NIPT till year-end on account of the pandemic, with the American Faculty of Obstetricians and Gynecologists (ACOG) additionally anticipated to endorse average-risk sooner or later given its medical utility, in Mah’s opinion.Reflecting one other constructive, the fourth technology NIPT (single-molecule counting assay) check was in a position to measure fetal fraction, a key milestone in response to Mah, and can proceed to be developed into 2021. Because the expertise might doubtlessly be utilized to DNA, RNA, epigenetic markers and proteins for extra medical functions equivalent to oncology, the analyst is wanting ahead to the completion of the preeclampsia verification in This fall 2020 and a doable 2H21 launch. “We imagine preeclampsia (~2.3 billion serviceable market) is a serious differentiator for Progenity, permitting them to cross-sell throughout the full-continuum of reproductive testing,” the analyst added.If that wasn’t sufficient, PROG signed its first GI Precision Medication partnership settlement with a top-20 Pharma firm in August. The Oral Biotherapeutic Supply System (OBDS), an ingestible drug and gadget mixture designed to exactly ship biologics systemically by way of a needle-free liquid jet injection into the submucosal tissues of the small gut, is about to be utilized as a part of the collaboration. Mah commented, “We imagine Progenity can signal further Pharma offers and stay up for the newsflow popping out on this entrance.”To sum all of it up, Mah mentioned, “We imagine Progenity shares are undervalued given the sturdy restoration within the core testing enterprise and a number of upcoming progress catalysts.”To this finish, Mah charges PROG an Obese (i.e. Purchase) together with a $17 value goal. Ought to his thesis play out, a twelve-month acquire of 105% might doubtlessly be within the playing cards. (To look at Mah’s monitor document, click on right here)Are different analysts in settlement? They’re. Solely Purchase rankings, 4, actually, have been issued within the final three months. Subsequently, the message is obvious: PROG is a Robust Purchase. Given the $13.33 common value goal, shares might climb 60% increased within the subsequent 12 months. (See PROG inventory evaluation on TipRanks)Tactile Programs Expertise (TCMD)Growing at-home remedy units, Tactile Programs Expertise desires to offer new remedies for lymphedema, which happens when the lymphatic system is impaired, disrupting regular transport of fluid throughout the physique, and continual venous insufficiency. Down 52% year-to-date, its $32.67 share value lands near its $29.47 52-week low. Thus, with enterprise traits enhancing, the Road is pounding the desk.Writing for Canaccord, analyst Cecilia Furlong acknowledges that the pandemic has hampered the corporate, with COVID-19 weighing on each volumes and gross sales. Within the second half of March, volumes have been down 50% in comparison with the primary half of the month, and TCMD’s affected person volumes in April and Could remained challenged. That being mentioned, traits began to enhance on the finish of Could.“Going ahead, given the overwhelming majority of TCMD’s clinician prospects follow in outpatient or office-based settings, we stay constructive on TCMD’s capability to exhibit higher insulation in opposition to COVID impacts and certain expertise a larger bounce-back relative to general med-tech quantity traits, with TCMD additional benefitting from its increasing utilizing of expertise to remotely have interaction with clinicians and assist sufferers,” Furlong defined.The analyst added, “Moreover, current traits amongst some suppliers to prescribe Flexitouch (a complicated intermittent pneumatic compression gadget to self-manage lymphedema and nonhealing venous leg ulcers) earlier alongside the remedy course of, as a method to scale back in-person contact, might present upside close to time period, in addition to doubtlessly transition to a longer-term tailwind.”On high of this, Furlong can be optimistic about new CEO Dan Reuvers and the reprioritization of the corporate’s funding and market improvement efforts. TCMD will shift focus away from its acquired Airwear product line, with it redirecting investments towards its Flexitouch and Entre (a pneumatic compression gadget used to help within the house administration of continual swelling and venous ulcers related to lymphedema and continual venous insufficiency) merchandise.“Given important under-penetration within the lymphedema/phlebolymphedema market focused by Flexitouch alongside the massive affected person inhabitants with restricted therapy choices at present focused by the agency’s Head & Neck platform, we view the mix of training and medical knowledge as key to additional creating and penetrating these markets… Going ahead, we anticipate administration to proceed to compile a broad base of medical knowledge to assist reimbursement and drive broad adoption,” Furlong commented.All of this prompted Furlong to maintain a Purchase score and $62 value goal on the inventory. This goal conveys her confidence in TCMD’s capability to soar 90% within the subsequent 12 months. (To look at Furlong’s monitor document, click on right here)Usually, different analysts are on the identical web page. With 3 Purchase rankings and 1 Maintain, the phrase on the Road is that TCMD is a Robust Purchase. The $62.33 common value goal brings the upside potential to 91%. (See TCMD inventory evaluation on TipRanks)uniQure N.V. (QURE)Final however not least we have now uniQure, which delivers healing gene therapies that would doubtlessly remodel the lives of sufferers. Though shares have fallen 44% year-to-date to $40, not a lot increased than its 52-week low of $36.20, a number of analysts nonetheless have excessive hopes.Representing SVB Leerink, 5-star analyst Joseph Schwartz acknowledges that shares struggled after information broke of its collaboration and licensing settlement with CSL Behring for AMT-061, QURE’s gene remedy for Hemophilia B, he argues the “shareholder base turnover is probably going now full as traders and QURE shift focus to next-in-line AMT-130, its AAV5 gene remedy for Huntington’s Illness (HD).”Schwartz additional added, “With the M&A premium now out of the inventory, we see the QURE’s present degree as a horny shopping for alternative for these traders within the firm’s up and coming CNS gene therapies, inner manufacturing, and sturdy mental property and knowhow.”Wanting extra carefully on the settlement with CSL Behring, QURE might be tasked with the completion of the pivotal Part 3 HOPE-B trial in addition to the manufacturing course of validation and manufacturing provide of AMT-061.In response to administration, 26-week Issue IX (FIX) knowledge from all 54 sufferers enrolled within the trial stays on monitor, and topline knowledge from the pivotal trial remains to be slated to learn out by YE20. It must be talked about that in a Part 2b dose-confirmation research, QURE reported 41% FIX exercise out to at least one 12 months. Moreover, Schwartz factors out that with HOPE-B progressing as deliberate, QURE has continued its manufacturing course of validation work forward of the anticipated BLA/MAA submissions within the U.S. and EU in 2021.On high of this, as a part of the deal, QURE is eligible to obtain greater than $2 billion together with a $450 million upfront money cost, $1.6 billion in regulatory and industrial milestones and double-digit royalties ranging as much as the low-twenties share of internet product gross sales.“With a strengthened money place, QURE is effectively funded to quickly advance CNS belongings together with AMT-130 (AAV5 gene remedy for Huntington’s Illness (HD)) and AMT-150 (AAV gene remedy for Spinocerebellar Ataxia Sort 3/SCA3)…We proceed to imagine that as QURE’s CNS pipeline belongings mature, the corporate might as soon as once more be a horny accomplice to bigger biopharma corporations which have just lately acquired many publicly traded gene remedy platforms with substantial manufacturing capabilities,” Schwartz famous.All the things that QURE has going for it satisfied Schwartz to reiterate an Outperform (i.e. Purchase) score. Together with the decision, he connected a $67 value goal, suggesting 68% upside potential from present ranges. (To look at Schwartz’s monitor document, click on right here)What does the remainder of the Road need to say? 9 Buys and three Holds have been issued within the final three months, so the consensus score is a Robust Purchase. As well as, the $69.89 common value goal signifies 75% upside potential. (See QURE inventory evaluation on TipRanks)To seek out good concepts for beaten-down shares buying and selling at enticing valuations, go to TipRanks’ Greatest Shares to Purchase, a newly launched instrument that unites all of TipRanks’ fairness insights.Disclaimer: The opinions expressed on this article are solely these of the featured analysts. The content material is meant for use for informational functions solely. It is extremely necessary to do your personal evaluation earlier than making any funding.